Hutchinson-Gilford progeria syndrome (HGPS), a rare disease that results in what appears to be premature aging, is caused by the production of a mutant form of prelamin A known as progerin. Progerin retains a farnesyl lipid anchor at its carboxyl terminus, a modification that is thought to be important in disease pathogenesis. Inhibition of protein farnesylation improves the hallmark nuclear shape abnormalities in HGPS cells and ameliorates disease phenotypes in mice harboring a knockin HGPS mutation (Lmna HG/+ ). The amelioration of disease, however, is incomplete, leading us to hypothesize that nonfarnesylated progerin also might be capable of eliciting disease. To test this hypothesis, we created knockin mice expressing nonfarnesylated progerin (Lmna nHG/+ ). Lmna nHG/+ mice developed the same disease phenotypes observed in Lmna HG/+ mice, although the phenotypes were milder, and mouse embryonic fibroblasts (MEFs) derived from these mice contained fewer misshapen nuclei. The steady-state levels of progerin in Lmna nHG/+ MEFs and tissues were lower, suggesting a possible explanation for the milder phenotypes. These data support the concept that inhibition of protein farnesylation in progeria could be therapeutically useful but also suggest that this approach may be limited, as progerin elicits disease phenotypes whether or not it is farnesylated.
Introduction
Hutchinson-Gilford progeria syndrome (HGPS) is a rare pediatric progeroid syndrome associated with the production of a mutant form of prelamin A (1) (2) (3) (4) (5) . Affected children appear normal at birth but soon develop multiple disease phenotypes resembling premature aging, including slow growth, loss of adipose tissue, alopecia, osteoporosis, and occlusive vascular disease (1, 3, 6) . HGPS is caused by a LMNA point mutation that alters mRNA splicing and leads to the production of a mutant prelamin A, progerin, that contains a 50-amino acid internal deletion within the carboxyl-terminal domain of the protein (1, 7) . Progerin, like wild-type prelamin A (8) , contains a carboxyl-terminal CaaX motif, which triggers protein farnesylation. The farnesyl lipid is added to the thiol group of the cysteine within the CaaX motif by a cytosolic enzyme, protein farnesyltransferase (FTase). Although the CaaX motif of progerin is intact, the 50-amino acid deletion eliminates the cleavage site for the endoprotease ZMPSTE24 (7, 9, 10) ; consequently, progerin cannot undergo the final endoproteolytic processing step that would normally clip off the carboxyl-terminal portion of the protein (including the farnesylated cysteine) (1, 2, 7) . Thus, farnesylated progerin accumulates in cells (7) . Progerin is targeted to the nuclear rim and causes misshapen nuclei, almost certainly by interfering with the integrity of the nuclear lamina (1, 2, 11-13).
Yang et al. (13) recently created a gene-targeted HGPS allele, Lmna HG , which exclusively yielded progerin. Heterozygous mice (Lmna HG/+ ) exhibit a variety of phenotypes similar to those in humans with HGPS (e.g., normality at birth followed by slow growth, osteoporosis, alopecia, partial lipodystrophy) (14) . Like fibroblasts from children with HGPS (1, 2), Lmna HG/+ mouse embryonic fibroblasts (MEFs) have misshapen nuclei (13) . We hypothesized that protein farnesylation could be important for disease pathogenesis (15) and further hypothesized that inhibiting protein farnesylation with a FTase inhibitor (FTI) might reduce the frequency of misshapen nuclei and ameliorate the disease phenotypes in Lmna HG/+ mice. Indeed, an FTI lowers the frequency of misshapen nuclei in Lmna HG/+ MEFs (13) . Also, in 2 independent studies (14, 16) , a highly selective FTI reduces disease phenotypes in Lmna HG/+ mice. An FTI also reduces disease phenotypes in ZMPSTE24-deficient mice (17) , where the farnesylated form of wildtype prelamin A accumulates (9, 10) . While an FTI was unequivocally efficacious in all 3 studies (14, 16, 17) , the amelioration of disease was far from complete; all of the FTI-treated mice ultimately developed severe phenotypes and succumbed to the disease.
The improved disease phenotypes in Lmna HG/+ mice treated with an FTI have prompted a clinical trial of an FTI treatment regimen in children with HGPS (18, 19) . Given the merciless nature of this disease, we hope that the FTI treatment will be efficacious. However, key questions remain about the scientific underpinnings of the FTI strategy. An FTI will leave HGPS cells with a distinctly abnormal lamin protein, nonfarnesylated progerin, and it is unclear whether that protein might retain the ability to elicit disease. An optimist might contend that nonfarnesylated progerin would be entirely nontoxic, given that FTIs can markedly reduce the frequency of misshapen nuclei in HGPS fibroblasts (13, 20, 21) . On the other hand, a pessimist would point to the less-than-complete amelioration of disease phenotypes in FTI-treated Lmna HG/+ mice (14, 16) and suggest that nonfarnesylated progerin might retain the capacity to cause disease.
The standard approach for assessing the functional importance of protein farnesylation is to examine the properties of a nonfarne-sylated mutant protein in which the cysteine of the CaaX motif has been replaced with a serine (22) (23) (24) . Serine is identical to cysteine, except that a side-chain sulfur atom is replaced with an oxygen. In the current study, we applied this approach and created a new line of HGPS mice expressing a nonfarnesylated version of progerin. Aside from the point mutation in the CaaX motif, the new genetargeted HGPS mice (Lmna nHG/+ ) were identical to the original mouse model (Lmna HG/+ ). We went on to compare the phenotypes of genetically identical Lmna nHG/+ and Lmna HG/+ mice.
Results

Production of Lmna nHG mice. We constructed a gene-targeting vec-
tor to create a mutant Lmna allele, Lmna nHG , designed to produce nonfarnesylated progerin ( Figure 1A ). The Lmna nHG allele is identical to the Lmna HG/+ allele created earlier (13) , except that the cysteine within the CaaX motif was replaced with a serine (which prevents protein farnesylation). Two targeted ES cell clones were identified by Southern blotting ( Figure 1B ) and used to create male chimeric mice, which were bred with C57BL/6 females to produce Lmna nHG/+ mice. Lmna nHG/+ MEFs produced progerin from the Lmna nHG allele and lamins A and C from the wild-type allele ( Figure 1C ). The electrophoretic mobility of progerin in Lmna nHG/+ MEFs was slightly slower than in Lmna HG/+ MEFs, which was predicted from the difference in farnesylation ( Figure  1C ). The point mutation in the Lmna nHG allele was verified by DNA sequencing ( Figure 1D ).
The absence of farnesylation in the progerin of Lmna nHG/+ MEFs was verified by metabolically labeling with anilinogeranyl diphosphate (AGPP), a farnesyl pyrophosphate analog (25) (26) (27) .
The incorporation of the AGPP into proteins can be monitored by Western blotting with an antibody against the anilinogeranyl moiety of AGPP ( Figure 2A ). As expected, farnesylated progerin was detected in Lmna HG/+ but not Lmna nHG/+ MEFs (Figure 2A ). Lamins B1 and B2 are farnesylated proteins with an electrophoretic mobility identical to that of progerin (intermediate between lamins A and C). Thus, it was not surprising to observe a farnesylated protein between lamin A and lamin C in all of the MEFs (Figure 2A) . However, following immunoprecipitation of the A-type lamins (i.e., lamin A, lamin C, and progerin), farnesylated progerin was observed only in Lmna HG/+ MEFs (Figure 2A) .
The farnesylation of progerin in Lmna HG/+ MEFs was abolished by treating the cells with an FTI (Figure 2A ). Western blots with an antibody against HDJ-2 provided further evidence that the FTI was active ( Figure 2B) .
Lmna nHG/+ mice develop severe disease phenotypes. Lmna nHG/+ mice developed the same spectrum of disease phenotypes observed in Lmna HG/+ mice, but the disease phenotypes were less severe (14) . Body-weight curves were abnormal in both male and female Lmna nHG/+ mice, compared with wild-type control mice (P < 0.0001 for both males and females) ( Figure 3, A and B) . However, the growth of Lmna nHG/+ mice was substantially better than that of Lmna HG/+ mice (P < 0.0001 for both males and females) ( Figure 3, A and B) .
Kaplan-Meier survival curves revealed that Lmna nHG/+ mice lived longer than Lmna HG/+ mice (P < 0.0001 for both males and females) ( Figure 3C ). Lmna HG/+ mice develop progressive rib fractures near the costovertebral joints with increasing age (14) ; these same bone abnormalities were observed in Lmna nHG/+ mice. However, the number of rib fractures at the time of death was lower in Lmna nHG/+ mice than in Lmna HG/+ mice (P < 0.0001 for both male and female mice) ( Figure 3D ), even though the Lmna nHG/+ mice were significantly older at the time of death (36.1 ± 0.69 weeks vs. 21.3 ± 0.84 weeks in Lmna HG/+ mice). Lmna nHG/+ mice had more body fat than Lmna HG/+ mice (P < 0.0001 for both males and females) ( Figure 3E ).
The reduced number of rib fractures and reduced kyphosis of the spine in Lmna nHG/+ mice were evident on μCT scans (Figure 4, A-F Figure 5A ). These experiments involved scoring nuclear shape in 4,000 cells per genotype. In 2 independent experiments, the percentage of misshapen nuclei was lower in Lmna nHG/+ MEFs than in Lmna HG/+ MEFs (P < 0.0001) ( Figure 5A) . Similarly, the percentage of misshapen nuclei was lower in Lmna nHG/nHG MEFs than in Lmna HG/HG MEFs (P < 0.0001) ( Figure 5A ). The spectrum of nuclear shape abnormalities differed in Lmna nHG/+ and Lmna HG/+ MEFs; nuclei containing folds accounted for a greater percentage of the total number of misshapen nuclei in Lmna nHG/+ and Lmna nHG/nHG MEFs (P < 0.0001) ( Figure 5A ).
Nuclear shape abnormalities in Lmna nHG/+ , Lmna nHG/nHG , Lmna HG/+ , and Lmna +/+ primary MEFs were examined in the presence or absence of an FTI (n = 4 cell lines/genotype; 4,000 cells/genotype counted) ( Figure 5B ). As expected, the FTI reduced the frequency of nuclear shape abnormalities in Lmna HG/+ MEFs (P < 0.0001), but it had no effect on Lmna nHG/+ or Lmna nHG/nHG MEFs ( Figure 5B ).
Normally, mature lamin A in wild-type MEFs is concentrated at the rim of the nucleus ( Figure 5C ). In Lmna nHG/nHG MEFs, we never observed a concentration of progerin at the nuclear rim ( Figure  5D ). In many cells, the nonfarnesylated progerin was highly concentrated in nuclear folds and blebs ( Figure 5 , D and E).
Progerin expression levels in Lmna nHG/+ and Lmna HG/+ mice. Disease phenotypes were less severe in Lmna nHG/+ mice than in Lmna HG/+ mice. To explore the potential explanation for this difference, we used Western blots to gauge progerin levels in Lmna HG/+ and Lmna nHG/+ mice. The levels of progerin relative to actin were lower in Lmna nHG/+ tissues (heart, liver, kidney, skull) than in Lmna HG/+ tissues (P < 0.0001) ( Figure 6 , A-D and F). Similarly, progerin levels relative to actin were lower in Lmna nHG/+ MEFs than in Lmna HG/+ MEFs (P < 0.0001) ( Figure 6 , E and F). The lower levels of progerin in Lmna nHG/+ MEFs and tissues raised the possibility that FTI treatment might reduce the steady-state levels of progerin in Lmna HG/+ MEFs and Lmna HG/+ mice. Indeed, this was the case. Treatment of Lmna HG/+ MEFs (n = 4 independently isolated cell lines) with an FTI reduced progerin levels relative to actin (P < 0.0001) ( Figure 7 , A and B). The FTI led to the appearance of nonfarnesylated prelamin A, as expected, and also reduced the levels of mature lamin A. The reduced levels of mature lamin A in FTI-treated MEFs were not surprising; previously, Toth et al. (20) showed that 2 chemically distinct FTIs markedly reduced the levels of mature lamin A in wild-type MEFs.
We also analyzed progerin levels in the hearts of Lmna HG/+ mice that had been treated with an FTI (ABT-100) for 3 or more months. The levels of progerin (relative to actin) were lower in hearts of FTI-treated Lmna HG/+ mice than in the hearts of mice treated with vehicle alone. This difference was significant (P < 0.0001) ( Figure 7 , C and D) and was observed in 2 independent experiments.
To examine the mechanism for the lower levels of progerin in Lmna nHG/+ MEFs and tissues, we measured progerin transcript levels in Lmna nHG/+ and Lmna HG/+ tissues. Progerin mRNA levels, as judged by RT-PCR, were not different in the 2 mouse models ( Figure 8 , A and B). The fact that progerin levels were lower in Lmna nHG/+ MEFs and tissues ( Figure 6 ) despite similar progerin transcript levels implied that the absence of farnesylation might accelerate progerin turnover. To test this possibility, we examined the disappearance of progerin in Lmna nHG/+ and Lmna HG/+ MEFs after labeling with [ 35 S]methionine. In the span of 4 days after labeling of the cells, the progerin/lamin C ratio in Lmna nHG/+ MEFs fell by 55.6%, while the progerin/lamin C ratio in Lmna HG/+ MEFs fell by 29.2%. We also examined by Western blot the progerin/actin ratios in Lmna nHG/+ and Lmna HG/+ MEFs before and after inhibition of Lmna expression with a mouse prelamin A-specific antisense oligonucleotide (29) . Two days after the second oligonucleotide transfection, the progerin/actin ratio fell by 39.4% in Lmna HG/+ MEFs and by 58.9% in Lmna nHG/+ MEFs. These observations are consistent with the lower steady state levels of progerin in Lmna nHG/+ MEFs and tissues ( Figure 6 ).
Discussion
In 2 independent studies (14, 16) , an FTI ameliorated disease phenotypes in Lmna HG/+ mice. However, the amelioration of disease was far from complete, leading us to consider the possibility that the nonfarnesylated form of progerin might itself be toxic and capable of eliciting disease. In the current study, we created a new line of HGPS-knockin mice expressing a nonfarnesylated version of progerin (Lmna nHG/+ ). Aside from a cysteine-to-serine substitution in the CaaX motif, Lmna nHG/+ mice were genetically identical to Lmna HG/+ mice (13) . The absence of progerin farnesylation in Lmna nHG/+ cells was verified with metabolic labeling experiments. Interestingly, the Lmna nHG/+ mice developed the same spectrum of disease phenotypes found in Lmna HG/+ mice (i.e., slow weight gain, rib fractures, loss of body fat, reduced survival). Thus, the principal message of this study is that a nonfarnesylated version of progerin is still toxic. However, the extent of disease phenotypes in Lmna nHG/+ mice was milder than in Lmna HG/+ mice. Also, the disease phenotypes in Lmna nHG/nHG mice were milder than those in Lmna HG/HG mice (14) . Thus, the second message of this study is that disease phenotypes are milder in the knockin mice expressing a nonfarnesylated version of progerin. The finding of less severe phenotypes in Lmna nHG/+ mice is consistent with the results of earlier FTI treatment studies (14, 16) .
Both Lmna nHG/+ and Lmna HG/+ mice produced progerin, and they were genetically identical - except at a single codon. However, the severity of the phenotypes was reduced in Lmna nHG/+ mice. We reasoned that one explanation might be lower steady-state levels of progerin in Lmna nHG/+ mice. Indeed, the levels of progerin, both in MEFs and tissues, were significantly lower in Lmna nHG/+ mice than in Lmna HG/+ mice despite similar levels of progerin transcripts, and follow-up studies in MEFs pointed to a more rapid disappearance of nonfarnesylated progerin. Reduced levels of progerin in the absence of farnesylation were not entirely surprising, as there are precedents for the absence of prenylation causing reduced steady-state levels of other CaaX proteins (30, 31) . It is quite plausible that the different steady-state levels of progerin in Lmna nHG/+ and Lmna HG/+ mice could explain the phenotypic differences in the 2 models. Higher levels of progerin expression are associated with more nuclear shape abnormalities (11) , and rare HGPS mutations yielding higher-than-usual progerin levels are associated with particularly severe forms of progeria (32) . Also, we found that Lmna HG/LCO mice (compound heterozygotes with 1 Lmna HG allele and 1 "lamin C-only" allele) have lower steady-state levels of progerin than Lmna HG/+ mice, despite identical levels of progerin transcripts. The reduced progerin levels in Lmna HG/LCO mice were accompanied by reduced disease phenotypes and a reduced frequency of misshapen nuclei (28) . Given the very positive effects of FTIs on nuclear shape in HGPS cells (13, 20, 21, 33, 34) , many will probably be quite surprised by the fact that nonfarnesylated progerin is toxic. However, viewed from the perspective of the human genetics of progeroid syndromes, one could argue that the findings are not particularly shocking. Very rare missense mutations in lamin A and lamin C - abnormalities that do not affect the carboxyl-terminal processing of prelamin A - can cause progeroid disorders in humans. For example, E145K and S143F mutations in lamins A/C clearly elicit progeria-like disease phenotypes (1, 35) , and compound heterozygosity for T528M and M540T substitutions in lamins A/C causes a progeroid syndrome that is similar to HGPS (36). Why these subtle structural variations cause progeroid syndromes rather than other "lamin A/C diseases" such as lipodystrophy or muscular dystrophy is not known, but at face value these genetic observations suggest that protein farnesylation is not "the entire story" in the pathogenesis of progeroid syndromes. Our current studies with nonfarnesylated progerin reinforce that view.
In our study, we eliminated protein farnesylation with the standard approach, which is to replace the cysteine of the CaaX motif with a serine (22) (23) (24) . The potential impact of a single amino acid substitution in lamin A or lamin C must be considered carefully, given that single amino acid substitutions in these proteins can elicit disease in humans (4). Indeed, one could argue that our conclusions require a caveat. The nonfarnesylated progerin in Lmna nHG/+ mice contains a missense mutation. One might conceivably argue - and it is clearly a formal possibility - that nonfarnesylated progerin with a cysteine in the CaaX motif (as would occur during FTI treatment of Lmna HG/+ mice) is 100% innocuous but that a nonfarnesylated progerin with the cysteine-to-serine substitution (as in Lmna nHG/+ mice) is toxic and elicits disease phenotypes similar to those associated with farnesylated progerin in untreated Lmna HG/+ mice. According to this reasoning, it is the point mutation in the Lmna nHG allele and not the 50-amino acid deletion that causes disease. There is no good experimental way to exclude this possibility, but this seems quite unlikely. First, the 50-amino acid deletion is a far more substantial structural alteration than a cysteine-to-serine substitution. Second, there is no precedent for a heterozygous Lmna missense mutation eliciting disease phenotypes in mice. Heterozygosity for L530P, H222P, and N195K mutations causes severe disease in humans (37-39) but no disease phenotypes in mice (40) (41) (42) .
Based on the efficacy of FTI treatment in Lmna HG/+ and Zmpste24 -/-mice (14, 16, 17) , a clinical trial of FTI therapy is under way in children with HGPS (18, 19) . What are the implications of our current studies for the treatment of HGPS? On the positive side, our current studies are consistent with our FTI treatment results (14, 16, 17) and suggest that reducing progerin farnesylation might be useful. On the other hand, our current studies suggest that the impact of an FTI could be limited. Despite a total absence of progerin farnesylation, Lmna nHG/+ mice still developed severe disease phenotypes. Thus, while FTIs may well ameliorate some phenotypes in children with HGPS, we doubt that FTIs will be a panacea, and we are skeptical that other strategies to interfere with protein prenylation, such as bisphosphonates (20) , will be any better. We believe that it will be important to continue to develop other therapeutic strategies, such as approaches to reduce the alternative splicing event that lies at the root of the disease (12), or to eliminate prelamin A transcripts with antisense approaches (29, 43) .
Methods
Knockin mice expressing nonfarnesylated progerin. The targeting vector for
the Lmna nHG allele is identical to that of the Lmna HG allele produced previously (13), except for a point mutation in exon 12 (in the 5′ arm of the vector) that changes the cysteine of the CaaX motif to a serine. The mutation was introduced into a plasmid containing the 5′ arm of the vector by site-directed mutagenesis with the QuikChange kit (Stratagene) with primer 5′-CAGAGCTCCCAGAACAGCAGCATCATGTAATCT-3′ (the single-base change is underlined) and a complementary reverse primer. The integrity of the completed gene-targeting vector was verified by restriction endonuclease digestion (the point mutation eliminates a PstI site) and DNA sequencing (13) .
Targeted 129/OlaHsd ES cell clones carrying the Lmna nHG allele were identified by Southern blotting with EcoRI-cleaved genomic DNA and a 348-bp 5′ flanking probe (13) . The probe detects a 10.4-kb band in the wild-type Lmna allele and a 9.3-kb band in the Lmna nHG allele. To produce chimeric mice, targeted ES cells were microinjected into C57BL/6 blastocysts. Chimeras were bred with C57BL/6 females to generate Lmna nHG/+ mice. Chimeras generated from Lmna HG/+ ES cells were used to generate Lmna HG/+ mice. Because Lmna nHG/+ and Lmna HG/+ mice were bred from chimeras, they were genetically identical (with 1 C57BL/6 chromosome and 1 129/OlaHsd chromosome) except for the point mutation in exon 12 of the Lmna nHG allele. Lmna nHG/+ mice were intercrossed to obtain Lmna nHG/nHG mice.
Genotyping of mice was performed by PCR with genomic DNA from tail biopsies and oligonucleotide primers 5′-TGAGTACAACCTGCGCTCAC-3′ and 5′-CAGACAGGAGGTGGCATGT-3′. The wild-type allele yields a 582-bp product, whereas the mutant allele yields a 186-bp product (13) .
In some experiments, Lmna HG/+ mice were treated with an FTI ABT-100 (14) . ABT-100 was kindly provided by David J. Frost (Abbott). The FTI was mixed in drinking water containing 0.4% hydroxy propyl methyl cellulose and 1.0% ethanol at a concentration of 0.3 mg/ml, so as to deliver a dose of approximately 39 mg/kg/d. The vehicle control consisted of drinking water with 0.4% hydroxy propyl methyl cellulose and 1.0% ethanol (14) . All mice were fed a chow diet and housed in a virus-free barrier facility with a 12-hour light/12-hour dark cycle. Body weights were assessed weekly. All animal studies were approved by UCLA's Animal Research Committee.
Cell culture. Primary MEFs were prepared from E13.5 embryos (10) . Earlypassage MEFs were plated in 6-well plates and grown to 75% confluency. In some experiments, protein farnesylation was blocked by incubating the cells with an FTI (10 μM ABT-100) for 48 hours.
Metabolic labeling to detect protein farnesylation. MEFs were incubated for 36 hours with an analogue of farnesol, 8-anilinogeraniol (AG) (30 μM in DMSO) (25) , in the presence and absence of an FTI (ABT-100, 5 μM). After entering cells, AG is incorporated into AGPP, which is used by protein FTase as a substrate for the modification of CaaX proteins such as progerin. The AG moiety of AGPP is transferred onto cellular proteins by FTase, competitive with endogenous pools of farnesyl diphosphate (25) . AG incorporation into endogenous cellular proteins was detected by Western blotting with a mouse monoclonal antibody specific for AG, diluted 1:5000 (25) .
Immunoprecipitation. MEFs were washed with PBS and harvested by scraping, then pelleted by centrifugation. The pellet was resuspended in 0.3 ml ice-cold lysis buffer (50 mM Tris, 0.15 M NaCl, 1 mM EDTA, 1% NP-40, 2.5 mg/ml deoxycholate, 1 mM PMSF, and 0.1% SDS in PBS) containing Complete Mini Protease Inhibitors (Roche) at 1× concentration, and incubated on ice for 10 minutes. After removing insoluble material by centrifugation, cell extracts were precleared by incubation with 25 μl of protein Gagarose (50% suspension in lysis buffer) (Roche) at 4°C for 30 minutes. Goat anti-lamin A/C antibody (15 μl) (Santa Cruz Biotechnology Inc.) was added to the precleared supernatant fluids and incubated at 4°C overnight with constant rotation. Immune complexes were isolated by the addition of protein G-agarose and incubation at 4° C for 2 hours, followed by centrifugation. The agarose gel was washed 5 times with ice-cold lysis buffer, and the bound proteins were released by boiling for 3 minutes in 2× sample loading buffer (Invitrogen). The agarose gel was removed by centrifugation, and the supernatant fluids were analyzed by SDS-polyacrylamide gel electrophoresis and Western blotting.
Metabolic labeling of lamins with [ 35 S]methionine. Lmna nHG/+ and Lmna HG/+ MEFs were grown in methionine-deficient medium (Invitrogen) and 10% fetal bovine serum (dialyzed against PBS) at 37°C overnight and then labeled with [ 35 S]methionine (200 μCi/ml; MP Biomedicals) for 24 hours. After labeling, cells were grown in standard DMEM/10% fetal calf serum. MEFs were harvested after the labeling period and daily for 4 days. Lamin A/C, progerin, and actin were immunoprecipitated and size fractionated by SDS-PAGE. The intensities of the progerin, lamin C, and actin bands were quantified with a Typhoon 9410 Phosphorimager (GE Healthcare), and the progerin/lamin C ratio was calculated.
Protein extraction and Western blots. Urea-soluble extracts were prepared from early-passage MEFs and tissues as described previously (44) . Freshly harvested mouse tissues (~150 mg) were snap-frozen in liquid nitrogen and then ground into a powder with a mortar and pestle; the powder was resuspended in 0.5 ml of urea-solubilization buffer (44) and ground in a glass tissue grinder for 2 minutes. Finally, the samples were sonicated and centrifuged at 14,000 g for 10 minutes. The extracts were size fractionated on 4%-12% gradient polyacrylamide Bis-Tris gels (Invitrogen) and the separated proteins transferred to nitrocellulose membranes for West- Western blots were performed on Lmna nHG/+ and Lmna HG/+ MEFs after partial inhibition of Lmna expression with a mouse prelamin A-specific antisense oligonucleotide (29) . Primary MEFs were plated on 6-well tissue culture plates and allowed to adhere overnight. The cells were washed with reduced serum Opti-MEM I medium (Invitrogen) and transfected with 30 nM of the mouse prelamin A-specific antisense oligonucleotide (ISIS 359445) or a control oligonucleotide (29) using 10 μl/ml Lipofectin (Invitrogen) at 37°C for 5 hours. The medium was then replaced with fresh culture medium (DMEM/10% FBS). The transfection was repeated the next day, and the cells were cultured for an additional 48 hours and then processed for Western blotting. The amount of progerin relative to lamin C was quantified with a LI-COR Odyssey scanner.
Immunofluorescence microscopy. Early-passage MEFs (matched for passage number) were grown on coverslips, fixed in 3% paraformaldehyde, permeabilized with 0.2% Triton X-100, and blocked with PBS containing 10% fetal bovine serum and 0.2% bovine serum albumin (15) ries) and 1:600 Alexa Fluor 488-conjugated anti-mouse antibody (A21202; Molecular Probes) and DAPI to visualize DNA. Images were obtained on an Axiovert 200 MOT microscope (Zeiss) with a ×63/1.25 oil immersion objective and processed with AxioVision 4.2 software (Zeiss). Nuclear shape (4,000 cells per genotype) was assessed in blinded fashion as described previously (13, 20, 28, 29) .
Analysis of rib fractures. The interior of the thorax of Lmna +/+ , Lmna nHG/+ , and Lmna HG/+ mice was photographed with a digital camera after the removal of the heart and lung tissue, and rib fractures were counted (14) (15) (16) (17) 28) .
Body fat measurements. Lmna +/+ , Lmna HG/+ , and Lmna nHG/+ mice were euthanized, and the major fat pads (reproductive, inguinal, and mesenteric) were isolated and weighed.
Extraction of RNA, cDNA synthesis, and RT-PCR. The isolation of RNA, cDNA synthesis, and RT-PCR was performed exactly as described previously (28) . The band intensities of the PCR fragments generated from the wild-type Lmna allele and the Lmna nHG/+ and Lmna HG/+ alleles were quantified with the Odyssey Infrared Imaging System and the results normalized to Arbp.
Microcomputed tomographic scanning and analyses. Lmna +/+ , Lmna nHG/+ , Lmna nHG/nHG , and Lmna HG/+ mice were examined by compact cone-beam tomography (μCT 40 scanner; SCANCO Medical). Scans were performed in the axial plane mounted in a cylindrical sample holder at medium resolution with a current of 143 μA and a voltage of 55 kVp.
Bone density of isolated rib segments was determined by μCT scanning in a cylindrical sample holder tube with a voltage of 55 kVp and current of 143 μA. Three-dimensional images were reconstructed in 2048 × 2048 pixel matrices with a standard convolution back-projection procedure with a Shepp-Logan filter, and a cortical volume of interest was defined for each measurement. The mineralized tissue was segmented with a threshold of 120 for all samples. A manufacturer-provided hydroxyapatite phantom of known density was used to calibrate the mean density of bone volume and the cortical thickness.
Statistics. Body weight curves were compared with repeated-measures ANOVA and the log-rank test. The bone density, number of rib fractures, and fat-pad weights were compared with the 2-tailed Student's t test. Means and SEM are shown. Differences in the percentages of misshapen nuclei were assessed by the χ 2 test. The number of surviving male and female mice was recorded weekly and expressed as a percentage of the total number of mice. The significance of differences was determined by the Kaplan-Meier method.
